Application of bromhexine metabolite VIII (NA 872) and bromhexine-glucose in treatment of adult respiratory distress syndrome; experimental and clinical results .
The authors study the changes in cardiopulmonary function after application of bromhexine metabolite VIII (NA 872) in an animal model of adult respiratory distress syndrome (ARDS) and bromhexine glucose solution (BGS) in ARDS patients. After damage of the lung alveolar surfactant by intratracheal atomization of 0.2 M HCl in LEWE Minipigs significant changes in lung compliance, dead space ventilation, venous admixture, alveolo-arterial oxygen tension difference, pulmonary vascular resistance, and oxygen uptake are present under application of NA 872 in comparison to untreated animals. In ARDS patients treated with BGS, pulmonary function is significantly ameliorated indicated by changes in static effective compliance, oxygen exchange ratio, and alveolo-arterial oxygen tension difference.
D000818:Animals; D001964:Bromhexine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D008168:Lung / Q000503:physiopathology*; D008170:Lung Compliance / Q000187:drug effects; D012119:Respiration; D012126:Respiratory Dead Space; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D013552:Swine / Q000502:physiology; D014655:Vascular Resistance; D014692:Ventilation-Perfusion Ratio
D001964:Bromhexine